| Dec 2020 | Scientists at University of Sassari used our scioPhospho platform to to analyse the synergy of BET and PARP inhibition in Small Cell Lung Cancer Cells:
"Among the I-BET762-associated and combination-associated differentially expressed proteins, 150 were common to both treatment conditions. ... Ranking I-BET762-associated and combination-associated DEPs by their differential expression revealed CHEK2 and PTEN to be among the top-downregulated proteins, whose deficiencies have been associated with HR defects and increased PARPi sensitivity. "
Fiorentino, F. P. et al. (2020) ‘BET-Inhibitor I-BET762 and PARP-Inhibitor Talazop. Synergy in Small Cell Lung Cancer Cells’, International Journal of Molecular Sciences, 21(24). doi: 10.3390/ijms21249595.